Boston Heart Diagnostics, Suite 100, 200 Crossing Boulevard, Framingham, MA 01702, USA
Dr. Schaefer founded Boston Heart Diagnostics Corporation with Dr. Bela Asztalos and Peter Parker in 2007, after developing the company’s proprietary HDL measurement technology and the Boston Heart Cholesterol Balance® test. They established HDL particle concentration as a more effective predictor for coronary heart disease (CHD) risk than traditional tests, and documented the utility of plasma sterol measurements to guide physician therapy to get patients to their LDL cholesterol goals. Dr. Schaefer is internationally recognized as a leader in the field of lipoprotein metabolism, and the diagnosis and management of lipoprotein disorders for the prevention of CHD.
Research Article
Clinical Utility of Corona Virus Disease-19 Immunoglobulin G, M, Spike Protein, and Neutralizing Antibodies in Health, Disease and Post-Vaccination
Author(s): Ernst J. Schaefer, Florence Comite, Latha Dulipsingh, Maxine Lang, Jessica Jimison, Martin M. Grajower, Nathan E. Lebowitz, Andrew S. Geller, Margaret R. Diffenderfer, Lihong He, Gary Breton, Michael L. Dansinger, Ben Saida, Chong Yuan and R. Travis Wilkes
Objective: About 80% of corona virus disease-19 (COVID-19) deaths due to severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) infection occur in subject’s ≥ 65 years of age, even though subjects in this age group
only account for about 10% of COVID-19 cases. Our objectives were to assess age effects and the clinical utility of
COVID-19 antibody levels in health, disease, and post-vaccination.
Methods: We measured serum SARS-CoV-2 immunoglobulin M (IgM), IgG and neutralizing antibodies using
immunoassay kits obtained from Diazyme (Poway, CA) and spike (S) protein antibodies using immunoassay kits
obtained from Roche Diagnostics (Indianapolis, IN).
Results: In 79,005 subjects, IgG and IgM levels were positive (≥1.0 arbitrary units [AU]/mL) in 5.29% and 3.25%
of subjects, respectively.. View more»